IVA - Inventiva S.A.

Inventiva S.A.

50 rue de Dijon
Daix 21121
France
33 3 80 44 75 00
https://www.inventivapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 109

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Frederic Cren	Co-Founder, CEO & Chairman	541.24k	N/A	1966
Dr. Pierre Broqua Ph.D.	Co-Founder, Chief Scientific Officer, Deputy CEO & Director	405.96k	N/A	1962
Mr. Jean Volatier	Chief Financial Officer	N/A	N/A	1965
Mr. Eric Duranson L.L.M.	Gen. Counsel	N/A	N/A	1974
Ms. Nathalie Harroy	Head of HR	N/A	N/A	1967
Dr. Irena Konstantinova	Head of Biology & Pharmacology	N/A	N/A	N/A
Dr. Michael Cooreman	Chief Medical Officer	N/A	N/A	1958
Mr. Jean-Paul Dutertre M.D.	Head of Pharmacovigilance	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Corporate Governance

Inventiva S.A.’s ISS Governance QualityScore as of May 1, 2023 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 9; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.